Trial Profile
A Phase 1 Study to Evaluate the Cardiac Safety of Orally Administered TAS-102 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 06 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Feb 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
- 10 Jun 2013 New trial record